Loading...
23 probiotics COVID-19 controlled studies, 12 RCTs
https://c19early.org/kmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Haran (RCT) 67% 0.33 [0.01-8.16] death 0/174 1/176 Improvement, RR [CI] Treatment Control Haran (RCT) 60% 0.40 [0.08-2.06] hosp. 2/174 5/176 Haran (RCT) 50% 0.50 [0.21-1.20] hosp./ER/UC 7/169 15/181 Haran (RCT) 20% 0.80 [0.61-1.04] recov. time 169 (n) 172 (n) Gutiérre.. (DB RCT) 35% 0.65 [0.53-0.80] no recov. 69/147 105/146 Veterini 29% 0.71 [0.41-1.22] viral time 15 (n) 15 (n) Navarro-Ló.. (RCT) 33% 0.67 [0.43-1.05] no recov. 14/24 13/15 Navarro-Ló.. (RCT) 53% 0.47 [0.20-1.08] no recov. 6/24 8/15 Navarro-Ló.. (RCT) 20% 0.80 [0.65-0.98] recovery 24 (n) 15 (n) Navarro-Ló.. (RCT) 26% 0.74 [0.54-1.01] recovery 24 (n) 15 (n) Hassan (RCT) 80% 0.20 [0.02-1.65] hosp. 1/50 5/50 Hassan (RCT) 18% 0.82 [0.56-1.21] no recov. 23/50 28/50 d'Ettorre 87% 0.13 [0.01-2.33] death 0/28 4/42 d'Ettorre 77% 0.23 [0.01-4.63] ventilation 0/28 2/42 d'Ettorre 88% 0.12 [0.02-0.61] progression 28 (n) 42 (n) Ceccarelli 64% 0.36 [0.18-0.68] death 10/88 34/112 Ceccarelli 15% 0.85 [0.48-1.50] ICU 16/88 24/112 Shah (RCT) 11% 0.89 [0.75-1.06] recov. time 30 (n) 30 (n) CT1 Shah (RCT) 11% 0.89 [0.76-1.05] hosp. time 30 (n) 30 (n) CT1 Shah (RCT) 83% 0.17 [0.04-0.68] no recov. 2/30 12/30 CT1 Shah (RCT) 4% 0.96 [0.80-1.16] no recov. 26/30 27/30 CT1 Li -12% 1.12 [0.74-1.69] no disch. 30/123 41/188 Li -60% 1.60 [1.21-2.11] no disch. 123 (n) 188 (n) Li -35% 1.35 [1.13-1.62] viral time 123 (n) 188 (n) Zhang 14% 0.86 [0.77-0.96] hosp. time 150 (n) 150 (n) Zhang 14% 0.86 [0.75-0.98] recov. time 150 (n) 150 (n) Zhang 17% 0.83 [0.75-0.93] viral time 150 (n) 150 (n) Ceccarelli 70% 0.30 [0.01-7.02] death 0/40 1/29 Ceccarelli 82% 0.18 [0.02-1.54] ICU 1/40 4/29 Ivashkin (RCT) -2% 1.02 [0.26-3.97] death 4/99 4/101 Ivashkin (RCT) 18% 0.82 [0.23-2.95] ventilation 4/99 5/101 Ivashkin (RCT) 27% 0.73 [0.24-2.22] ICU 5/99 7/101 Ivashkin (RCT) 5% 0.95 [0.84-1.08] recov. time 99 (n) 101 (n) Zhang 65% 0.35 [0.02-8.30] ventilation 0/25 1/30 Zhang 67% 0.33 [0.10-1.05] antibody 3/25 11/30 Saviano (RCT) 67% 0.33 [0.01-7.95] death 0/40 1/40 Saviano (RCT) 86% 0.14 [0.01-2.68] ICU 0/40 3/40 Saviano (RCT) 26% 0.74 [0.30-1.83] hosp. time 40 (n) 40 (n) Trinchieri 78% 0.22 [0.03-1.93] death 1/21 3/14 Trinchieri 78% 0.22 [0.09-0.55] misc. 4/21 12/14 Trinchieri 10% 0.90 [0.76-1.08] misc. 19/21 14/14 Di Pierro (RCT) 62% 0.38 [0.11-1.25] death 3/25 8/25 Di Pierro (RCT) 0% 1.00 [0.45-2.24] ICU 8/25 8/25 Louca 8% 0.92 [0.85-0.99] cases population-based cohort Di Pierro (RCT) 98% 0.02 [0.00-0.33] cases 0/64 24/64 COVIDENCE UK Holt 30% 0.70 [0.45-1.10] cases 20/909 426/14,318 Ahanchian (DB RCT) 73% 0.27 [0.03-2.25] symp. case 1/29 4/31 Ahanchian (DB RCT) 85% 0.15 [0.01-2.73] cases 0/29 3/31 PROTECT-EHC Wischme.. (DB RCT) 33% 0.67 [0.38-1.17] m/s case 16/91 24/91 PROTECT-EHC Wischme.. (DB RCT) 38% 0.62 [0.41-0.93] symp. case 24/91 39/91 PROTECT-EHC Wischme.. (DB RCT) 27% 0.73 [0.37-1.45] recov. time 91 (n) 91 (n) PROTECT-EHC Wischme.. (DB RCT) 43% 0.57 [0.25-1.30] cases 8/91 14/91 Rodrigue.. (DB RCT) 9% 0.91 [0.12-6.70] cases 2/127 2/128 Catinean 40% 0.60 [0.41-0.88] recovery 60 (n) 60 (n) Catinean 38% 0.62 [0.42-0.93] fever 60 (n) 60 (n) Probiotics COVID-19 outcomes c19 earlyOctober 2023 1 CT: study uses combined treatment Favors probiotics Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
